NCT00057122View on ClinicalTrials.gov

Tuberculosis Prevention for HIV Infected Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

1,148

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

November 30, 2008

Study Completion Date

June 30, 2009

Conditions
HIV InfectionsTuberculosis
Interventions
DRUG

Isoniazid

300mg

DRUG

Rifapentine

Rifapentine 900 mg

DRUG

Rifampin

Rifampin 600 mg

Trial Locations (1)

Unknown

Chris Hani Baragwanath Hospital, Soweto

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00057122 - Tuberculosis Prevention for HIV Infected Adults | Biotech Hunter | Biotech Hunter